
Francesco Onida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3827970/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 2002, 99, 840-849.	0.6	356
2	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of Clinical Oncology, 2015, 33, 3766-3773.	0.8	328
3	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 2017, 129, 1753-1762.	0.6	278
4	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood, 2008, 112, 895-902.	0.6	192
5	Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2010, 28, 4492-4499.	0.8	191
6	Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). Journal of Clinical Oncology, 2017, 35, 2157-2164.	0.8	183
7	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood, 2014, 123, 2333-2342.	0.6	162
8	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica, 2010, 95, 476-484.	1.7	144
9	Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut, 2008, 57, 211-217.	6.1	142
10	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 872-880.	2.0	141
11	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	3.8	136
12	<i>RAS</i> Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant. Clinical Cancer Research, 2010, 16, 2246-2256.	3.2	123
13	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal, 2015, 5, e333-e333.	2.8	117
14	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	0.6	98
15	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	1.7	93
16	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults. HemaSphere, 2018, 2, e150.	1.2	91
17	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood, 2013, 122, 4111-4118.	0.6	90
18	Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis. Journal of Clinical Oncology, 2014, 32, 3347-3348.	0.8	85

#	Article	IF	CITATIONS
19	Characteristics and outcome of patients with Philadelphia chromosome negative,bcr/abl negative chronic myelogenous leukemia. Cancer, 2002, 95, 1673-1684.	2.0	82
20	Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 2116-2127.	6.3	79
21	Should the standard dimethyl sulfoxide concentration be reduced? Results of a <scp>E</scp> uropean <scp>G</scp> roup for <scp>B</scp> lood and <scp>M</scp> arrow <scp>T</scp> ransplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. Transfusion, 2014, 54, 2514-2522.	0.8	75
22	Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplantation, 2004, 33, 1005-1009.	1.3	73
23	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 399-406.	3.7	70
24	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nature Communications, 2018, 9, 2192.	5.8	66
25	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. American Journal of Hematology, 2013, 88, 581-588.	2.0	61
26	Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring System. Leukemia and Lymphoma, 2007, 48, 1150-1160.	0.6	60
27	A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia, 2018, 32, 413-418.	3.3	58
28	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica, 2021, 106, 375-383.	1.7	57
29	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612.	2.2	56
30	Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Digestive and Liver Disease, 2011, 43, 946-952.	0.4	53
31	Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplantation, 2017, 52, 53-58.	1.3	53
32	Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica, 2011, 96, 291-297.	1.7	51
33	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia, 2017, 31, 2449-2457.	3.3	51
34	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. Journal of Crohn's and Colitis, 2018, 12, 476-488.	0.6	43
35	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 885-890.	2.0	42
36	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer Journal, 2015, 5, e270-e270.	2.8	39

#	Article	IF	CITATIONS
37	Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2017, 177, 759-765.	1.2	38
38	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica, 2014, 99, 1582-1590.	1.7	36
39	Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica, 2013, 98, 1344-1352.	1.7	35
40	Primary cutaneous Bâ€cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. Cancer Medicine, 2016, 5, 2740-2755.	1.3	34
41	Autologous Haematopoietic Stem Cell Transplantation for Crohn's Disease: A Retrospective Survey of Long-term Outcomes From the European Society for Blood and Marrow Transplantation. Journal of Crohn's and Colitis, 2018, 12, 1097-1103.	0.6	29
42	Chronic myelomonocytic leukemia: myeloproliferative variant. Psychophysiology, 2004, 3, 218-26.	1.1	28
43	Reply to "COVID-19 in persons with haematological cancers†a focus on myeloid neoplasms and risk factors for mortality. Leukemia, 2020, 34, 1957-1960.	3.3	26
44	Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. Frontiers in Immunology, 2020, 11, 569381.	2.2	26
45	Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. PLoS ONE, 2013, 8, e74368.	1.1	25
46	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. Bone Marrow Transplantation, 2017, 52, 163-166.	1.3	24
47	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2021, 56, 1391-1401.	1.3	24
48	Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial. Blood, 2020, 136, 53-54.	0.6	24
49	Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leukemia and Lymphoma, 2006, 47, 417-423.	0.6	23
50	Paclitaxel-Dependent Prolonged and Persistent Complete Remission Four Years from First Recurrence of Secondary Breast Angiosarcoma. Tumori, 2009, 95, 828-831.	0.6	22
51	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab. Bone Marrow Transplantation, 2020, 55, 1580-1587.	1.3	21
52	Metabolic syndrome in patients with hematological diseases. Expert Review of Hematology, 2012, 5, 439-458.	1.0	15
53	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. HemaSphere, 2020, 4, e497.	1.2	14
54	Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report. Clinical Case Reports (discontinued), 2015, 3, 650-655.	0.2	13

#	Article	IF	CITATIONS
55	OP021 Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party. Journal of Crohn's and Colitis, 2018, 12, S014-S015.	0.6	13
56	GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms. Transplantation and Cellular Therapy, 2022, 28, 96.e1-96.e11.	0.6	13
57	Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). Leukemia Research, 2013, 37, 809-815.	0.4	11
58	Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms: An Update on Risk Stratification, Molecular Genetics, and Therapeutic Approaches Including Allogeneic Hematopoietic Stem Cell Transplantation. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e398-e412.	1.8	11
59	Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. Frontiers in Immunology, 2020, 11, 584520.	2.2	11
60	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2017, 23, 1102-1109.	2.0	9
61	Models of Prognostication in Chronic Myelomonocytic Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 513-521.	1.2	9
62	â€~Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplantation, 2018, 53, 58-63.	1.3	7
63	Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy). Blood Advances, 2020, 4, 2996-2999.	2.5	7
64	Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget, 2016, 7, 39458-39472.	0.8	7
65	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bone Marrow Transplantation, 2022, 57, 949-958.	1.3	7
66	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leukemia and Lymphoma, 2016, 57, 2370-2374.	0.6	5
67	Prospective evaluation of metabolic syndrome and its features in a single-center series of hematopoietic stem cell transplantation recipients. Annals of Hematology, 2018, 97, 2471-2478.	0.8	5
68	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplantation, 2020, 55, 2077-2086.	1.3	5
69	Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial). Blood, 2014, 124, 320-320.	0.6	5
70	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood, 2016, 128, 4320-4320.	0.6	5
71	Diagnosis and management of chronic myelomonocytic leukemia. Current Hematologic Malignancy Reports, 2008, 3, 31-36.	1.2	4
72	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. Expert Opinion on Biological Therapy, 2017, 17, 821-836.	1.4	4

#	Article	IF	CITATIONS
73	Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e256-e262.	2.0	4
74	Critical concepts and management recommendations for cutaneous Tâ€cell lymphoma: A consensusâ€based position paper from the Italian Group of Cutaneous Lymphoma. Hematological Oncology, 2021, 39, 275-283.	0.8	4
75	An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. Blood, 2014, 124, 530-530.	0.6	4
76	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 1072-1078.	1.3	4
77	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 4581-4581.	0.6	3
78	An expert consensus report on mycosis fungoides in Italy: epidemiological impact and diagnostic-therapeutic pathway. Italian Journal of Dermatology and Venereology, 2021, 156, 413-421.	0.1	3
79	Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA. Thrombosis and Haemostasis, 2021, , .	1.8	3
80	Haploidentical Hematopoietic Stem Cell Transplant Complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant From the Same Donor With No Immunosuppression but C5 Inhibition. Transplantation, 2019, 103, e48-e51.	0.5	2
81	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. Transplantation and Cellular Therapy, 2021, 27, 328.e1-328.e6.	0.6	2
82	Myelodysplastic/Myeloproliferative Neoplasms. , 2019, , 561-568.		2
83	Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial). Blood, 2018, 132, 1019-1019.	0.6	2
84	High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect. Blood, 2013, 122, 2059-2059.	0.6	2
85	Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up. Blood, 2013, 122, 2094-2094.	0.6	2
86	Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R). Blood, 2014, 124, 531-531.	0.6	2
87	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. Bone Marrow Transplantation, 2022, 57, 896-902.	1.3	2
88	Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse. Leukemia and Lymphoma, 2022, 63, 2743-2746.	0.6	2
89	OC-014â€Clinical and Endoscopic Improvement following Hemopoietic Stem Cell Transplantation vs Mobilisatiion alone in Crohn'S Disease. Gut, 2013, 62, A6.2-A6.	6.1	1
90	Uncommon Breast Malignancies: Presentation Pattern, Prognostic Issue and Treatment Outcome in an Italian Single Institution Experience. Tumori, 2013, 99, 39-44.	0.6	1

#	Article	IF	CITATIONS
91	Acquired platelet dysfunction and overproduction of platelet cyclic AMP in two patients with myeloid malignancies. Platelets, 2019, 30, 1053-1056.	1.1	1
92	Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study. Blood, 2018, 132, 3404-3404.	0.6	1
93	Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation. Blood, 2010, 116, 3043-3043.	0.6	1
94	Chronic Myelomonocytic Leukemia in Young Patients: Molecular and Cytogenetic Predictors of Survival and Treatment Outcome. Blood, 2014, 124, 4633-4633.	0.6	1
95	Total Skin Electron Beam Therapy in Patients with Advanced Cutaneous T Cell Lymphoma Undergoing Allogeneic Stem Cell Transplantation: A Single Centre Experience. Blood, 2019, 134, 2042-2042.	0.6	1
96	A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin. Clinical Case Reports (discontinued), 2021, 9, 978-982.	0.2	1
97	Lettera al Direttore. Pharmacoeconomics Italian Research Articles, 2009, 11, 197-197.	0.2	Ο
98	OP0025â€Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis is Effective in Inducing Prolonged Remission of Disease Activity: Results from Long-Term Follow-Up. Annals of the Rheumatic Diseases, 2014, 73, 69.1-69.	0.5	0
99	SAT0471â€Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis is More Effective Than Conventional Therapies in Inducing Disease Remission and Prologing Survival: Table 1. Annals of the Rheumatic Diseases, 2015, 74, 831.2-831.	0.5	0
100	Gv <scp>HD</scp> prophylaxis in nonâ€haploidentical allogeneic peripheral blood stem cell transplantation: beyond the standard to prevent relapse in patients with highâ€risk chronic lymphoproliferative diseases?. European Journal of Haematology, 2016, 96, 7-8.	1.1	0
101	DOP057 ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review. Journal of Crohn's and Colitis, 2018, 12, S070-S071.	0.6	0
102	Long-term remission of relapsed subcutaneous panniculitis-like T-cell lymphoma with cyclosporine A: A case report. European Journal of Cancer, 2018, 101, S24.	1.3	0
103	Allogeneic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: 2018 update of the Milan experience. European Journal of Cancer, 2018, 101, S35-S36.	1.3	0
104	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.2	0
105	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato, 2021, 2, 79-88.	0.2	0
106	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. SSRN Electronic Journal, 0, , .	0.4	0
107	In Vitro Colony Growth, RAS Genes Sequencing, and Expression of Bcl-2 and Bax Proteins in Chronic Myelomonocytic Leukemia Blood, 2004, 104, 2379-2379.	0.6	0
108	Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells Blood, 2007, 110, 4196-4196.	0.6	0

7

#	Article	IF	CITATIONS
109	Factors affecting prognosis in myelofibrosis. F1000 Medicine Reports, 2009, 1, .	2.9	0
110	New SMAC-Mimetic Compounds Strongly Induce In Vitro Apoptosis of Human Lymphocytes From Patients with Chronic Lymphocytic Leukemia. Blood, 2010, 116, 1835-1835.	0.6	0
111	Molecular Determinants of Decitabine Response in Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 4644-4644.	0.6	0
112	Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience. Blood, 2015, 126, 4403-4403.	0.6	0
113	Tyrosin-Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood, 2015, 126, 5148-5148.	0.6	0
114	Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS). Blood, 2016, 128, 3473-3473.	0.6	0
115	Long-Term Outcome of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mycosis Fungoides and Sézary Syndrome: The Milan Experience. Blood, 2018, 132, 4655-4655.	0.6	0
116	Prognostic Value of Cpss Cytogenetic Risk Classification in Patients with CMML after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study of the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 2182-2182.	0.6	0
117	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 4390-4390.	0.6	0
118	PF758ÂMULTIâ€CENTER, PHASE II STUDY ON HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING A RIC REGIMEN AND POSTâ€TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH POOR PROGNOSIS LYMPHOMAS. HemaSphere, 2019, 3, 333.		0
119	Haploidentical Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Report of Four Consecutive Cases from a Single Center. Blood, 2019, 134, 5744-5744.	0.6	0
120	Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP). Blood, 2021, 138, 3959-3959.	0.6	0
121	Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT. Blood, 2021, 138, 3953-3953.	0.6	0
122	Simoultaneous Home Palliative Care in Onco-Hematological Patients: An Italian Single Institution Experience. Blood, 2020, 136, 2-3.	0.6	0
123	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. Blood, 2020, 136, 39-40.	0.6	0
124	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. Blood, 2020, 136, 3-4.	0.6	0